PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27743887-8	2017	Our patient shows that folinic acid therapy can ameliorate the clinical symptoms, white matter disturbances, cortical insults, and peripheral neuropathy of cerebral folate deficiency caused by FOLR1 mutation.	Leucovorin	23-35	folate receptor alpha	Homo sapiens	193-198	
34442354-8	2021	Autoantibodies against folate receptor alpha (FRalpha) are present in about 70% of the children with a diagnosis of ASD, and a significant number of these children respond to oral folinic acid with overall improvements in speech, language and social interaction.	Leucovorin	180-192	folate receptor alpha	Homo sapiens	23-44	
34008900-8	2021	It is crucial to recognize FOLR1 signs and establish an early clinical and molecular diagnosis in order to provide timely folinic acid treatment and improve outcome.	Leucovorin	122-134	folate receptor alpha	Homo sapiens	27-32	
27363740-7	2016	The patient with FOLR1 gene mutation had extremely low CSF 5MTHF and total folate, though these values normalized after folinic acid supplementation.	Leucovorin	120-132	folate receptor alpha	Homo sapiens	17-22	
28155935-0	2017	Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin.	Leucovorin	93-103	folate receptor alpha	Homo sapiens	0-22	
28155935-2	2017	Here, we have investigated the concentration- and ligand-dependent aggregation of folate binding protein (FBP), focusing in particular on folic acid, an important vitamin and targeting agent; methotrexate, an antifolate drug used to treat cancer and rheumatoid arthritis; and leucovorin which is used to decrease methotrexate toxicity.	Leucovorin	276-286	folate receptor alpha	Homo sapiens	106-109	
27328863-0	2016	Neurological improvement following intravenous high-dose folinic acid for cerebral folate transporter deficiency caused by FOLR-1 mutation.	Leucovorin	57-69	folate receptor alpha	Homo sapiens	123-129	
27328863-12	2016	CONCLUSIONS: This report illustrates that cerebral folate transporter deficiency caused by FOLR-1 mutations is a treatable condition and can potentially be cured by folinic acid treatment.	Leucovorin	165-177	folate receptor alpha	Homo sapiens	91-97	
25841994-8	2015	The identification of this FRalpha-STAT3 signal transduction pathway activated by folic and folinic acid contributes to the understanding of the involvement of folic acid in preventing neural tube defects as well as in tumour growth.	Leucovorin	92-104	folate receptor alpha	Homo sapiens	27-40